The EIF4A2 Knockout HT29 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population targeting the EIF4A2 gene in the HT29 human colorectal adenocarcinoma line. This polyclonal pool enables loss-of-function studies of the ATP-dependent RNA helicase EIF4A2, a core component of the eIF4F translation initiation complex.
The HT29 cell line, derived from a colorectal adenocarcinoma of a 44-year-old female, is a widely used intestinal epithelial model. These adherent epithelial cells retain key features of colon carcinoma, offering a robust platform for investigating cancer-relevant signaling and translation control.
EIF4A2 is an ATP-dependent RNA helicase that unwinds secondary structures in the 5?? untranslated regions of mRNAs, a critical step for 43S pre?initiation complex binding and cap?dependent translation initiation. As an integral subunit of the eIF4F complex, EIF4A2 directly interacts with the cap?binding protein eIF4E and the scaffold eIF4G, and cooperates with auxiliary factors eIF4B and eIF4H. Its enzymatic activity is positively regulated by mTORC1 signaling: mTORC1 phosphorylates EIF4EBP1, releasing eIF4E to promote eIF4F assembly, and PDCD4 acts as a repressor that must be phosphorylated and degraded to derepress EIF4A2. Key downstream effectors whose translation relies on EIF4A2 helicase activity encompass oncogenic and cell?cycle regulators such as MYC, CCND1, BCL2, and VEGFA??all containing highly structured 5??UTRs. Consequently, EIF4A2 serves as a critical node that transduces growth?promoting signals from the PI3K/AKT/mTOR pathway into selective synthesis of proteins driving proliferation and survival. Additional pathway involvement includes MKNK1-mediated phosphorylation of eIF4E and eEF2K-dependent elongation control, further integrating translation regulation.
In HT29 colorectal adenocarcinoma cells, disruption of EIF4A2 is anticipated to block the efficient translation of these structured 5??UTR?containing oncogenic messengers, thereby attenuating cell proliferation, survival, and tumorigenic potential. This loss?of?function model provides a disease?relevant platform for dissecting the dependency of colon carcinoma on cap?dependent translation and for evaluating the impact on malignant phenotypes such as anchorage?independent growth and invasion.
This polyclonal knockout population is ideal for detailed mechanistic studies, including polysome profiling and ribosome profiling to assess global translation alterations, RIP?seq to map direct EIF4A2 mRNA targets, and western blotting to quantify downstream effectors such as MYC and CCND1. Functional assays such as MTT and BrdU proliferation measurements, along with drug sensitivity screens using translation inhibitors like silvestrol, enable pharmacological and genetic validation of the translational machinery as a therapeutic vulnerability in colorectal cancer. Researchers can also employ the model to investigate cross?talk between mTOR signaling and translational reprogramming. For further details or custom inquiries, please contact Ascent Research.
